12 results about "Streptomyces albus" patented technology

This invention relates to the fields of bioengineering and fermentation engineering, and discloses a genetically engineered *Streptomyces albopictus* strain that produces high levels of ε-polylysine and its fermentation production process. This genetically engineered strain uses *Streptomyces albopictus* strains acclimated to ε-polylysine tolerance as a chassis, and its genome integrates... ppc and dapf Through expression box, heterogeneous asd Expression cassettes, containing secretory signal peptides lysp Fusion expression cassettes and D404A / K499A point mutations pls Expression cassette. The fermentation process employs a two-stage pH control strategy, maintaining a neutral environment during the cell growth phase and adjusting to an acidic environment during product synthesis. This invention improves ε-polylysine yield through a synergistic strategy of enhancing precursor supply, constructing efflux detoxification channels, and increasing synthase activity; combined with an acidic fermentation process, it effectively inhibits product degradation, yielding a high-molecular-weight and highly uniform target product suitable for industrial production.

The invention discloses a method for increasing the fermentation yield of mernomycin A based on a reinforced chassis strain glycosyl donor. Specifically, in the heterologous expression process of a sirnomycin A biosynthetic gene cluster in a chassis strain Streptomyces albus J1074, a glycosyl donor synthesis module gene and a resistance gene (MaPBP) are introduced at the same time, and on the basis of improving a glycosyl biosynthetic donor, the physiological tolerance of the chassis strain is also enhanced. Compared with a high-yield strain Streptomyces albus LX03 (CGMCC NO. 20985) of which the tolerance is only optimized, the yield of the strain Streptomyces albus LX02: pJQK610 subjected to genetic engineering optimization is improved by 285%, and the yield reaches 114 mg / L. The strain disclosed by the invention has the advantages that the yield of the strain Streptomyces albus LX02: pJQK610 is improved by 285%, and the yield of the strain Streptomyces albus LX02: pJQK610 is improved by 285%. The invention provides a high-yield technology for improving heterologous expression of the mernomycin A through collaborative optimization of precursor supply and physiological tolerance, and provides reference for efficient production of the medicine.

The application discloses a kind of compound medicament and wheat stem base rot comprehensive prevention method, belong to plant disease control technical field.The application is prepared by using compound medicament and seed coating agent by combining streptomyces albus S86 fermentation liquor with kiralate medicament, it is found that the combination has obvious synergistic effect, the inhibition rate of false smut fungus spore germination is higher than single-agent medicament, it is 72.65%;Wheat stem base rot has better field control effect, disease index is 0.02, and the control effect is 73.85%.Field intuition shows that the disease degree of streptomyces albus S86 fermentation liquor and kiralate medicament combination treatment group is lighter than other treatment groups as a whole.This provides a basis for the biological control of wheat stem base rot in the future, and has wide application prospect.

The invention relates to an engineering bacterium for producing UK-2A and application of the engineering bacterium. The UK-2A biosynthetic gene cluster is reconstructed by adding a promoter in front of a ukaA gene of the UK-2A biosynthetic gene cluster, adding a promoter rpsLp-cf in front of a ukaB gene and adding a promoter SP23 in front of a ukaC gene, an expression vector containing the reconstructed UK-2A gene cluster is constructed and introduced into streptomyces albus J1074, UK-2A is efficiently produced by using a better fermentation culture medium, and the UK-2A biosynthetic gene cluster has the advantages that the UK-2A biosynthetic gene cluster is high in yield; the shake-flask fermentation yield of the engineering bacteria reaches 1500 micrograms / mL or above, and compared with the engineering bacteria of the UK-2A gene cluster before reconstruction, the UK-2A yield is greatly improved.

The invention relates to the technical field of microbial fermentation engineering, in particular to a streptomyces albus culture medium, a fermentation method, a biological bacteriostatic agent and application of the biological bacteriostatic agent. The culture medium contains a carbon source, a nitrogen source and inorganic salt in a specific concentration range, and the pH is neutral. When the culture medium is used for fermenting specifically preserved streptomyces albus ZJU527, a biological bacteriostatic agent can be efficiently prepared. The effective components of the bacteriostatic agent comprise tetramycin A, tetramycin B, tetraene rhzomorph A and tetraene rhzomorph B, and the bacteriostatic agent has a remarkable inhibition effect on various microorganisms such as bacillus subtilis, escherichia coli, saccharomycetes and fusarium graminearum, especially on plant pathogenic fungi fusarium graminearum.

The invention discloses a spinosad synthetic strain metabolism model reconstruction method integrating protein structure comparison and application, and belongs to the field of system biology. The streptomyces albus mature GEMs are taken as a template, protein sequence comparison and structure comparison are comprehensively utilized, the gene (protein) homologous relationship of the streptomyces albus and the saccharopolyspora spinosa is established, and the high-quality saccharopolyspora spinosa GEMs are obtained by combining additional gene function annotation, gap filling and the like. The GEMs can systematically represent all metabolic enzyme functions of saccharopolyspora spinosa, accurate prediction from genotype to strain phenotype is realized, and systematic design research of saccharopolyspora spinosa cell factories is facilitated.

The application discloses application of Streptomyces noursei PUNP1 in production of gougerotin and belongs to the technical field of biotechnology.The preservation number of the Streptomyces noursei PUNP1 is CGMCC No.34068, which is obtained by overexpressing a PUNP1 gene in Streptomyces albus, and the nucleotide sequence of the PUNP1 gene is shown as SEQ ID NO:1.It is found through experiments that the content of gougerotin in a fermentation product after shake flask fermentation and fermentation tank fermentation of the Streptomyces noursei PUNP1 is as high as 2.56 g / L and 3.74 g / L respectively.It is also found that the ability of the gougerotin produced by the fermentation of the Streptomyces noursei PUNP1 to inhibit Rhodotorula is significantly higher than that of a wild type strain, which indicates that the Streptomyces noursei PUNP1 can significantly improve the production of gougerotin in a fermentation product.The application provides a scientific basis for improving the production of gougerotin by Streptomyces albus and cell resistance.

The invention discloses streptomyces G18 and application thereof, and relates to the technical field of biological control. The streptomycete G18 disclosed by the invention is preserved in the China Center for Type Culture Collection on June 05, 2025, and the preservation number is CCTCC NO: M 20251269. The streptomyces albus is streptomyces albus, the streptomyces albus can be used for preventing and treating the camellia oleifera anthracnose, the inhibition rate of fermentation liquor of the streptomyces albus on a camellia oleifera anthracnose pathogenic bacterium colletotrichum gloeosporioides YC12 strain is as high as 80%, the inhibition rate of n-butyl alcohol extract of the fermentation liquor of the streptomyces albus on the YC12 strain is as high as 97.65%, the growth of the YC12 strain is almost completely inhibited, and the streptomyces albus can be used for preventing and treating the camellia oleifera anthracnose. The streptomyces G18 has a good prevention and treatment effect on the camellia oleifera anthracnose, and can be prepared into a biological agent for biological prevention and treatment on the camellia oleifera anthracnose.

The invention discloses streptomyces albus genetically engineered bacteria with high yield of 5-hydroxytryptamine as well as a construction method and application of the streptomyces albus genetically engineered bacteria, and belongs to the technical field of microbial genetic engineering and fermentation engineering. The genetically engineered bacterium is constructed by taking streptomyces albus of which tryptophan bioxidase is knocked out as a starting bacterium, introducing a tryptophan hydroxylase coding gene and a 5-hydroxytryptophan decarboxylase coding gene and knocking out at least one of acyltransferase genes ata1, ata2, ata3, ata4 and ata5 in a genome of the streptomyces albus while knocking out the tryptophan hydroxylase coding gene and the 5-hydroxytryptophan decarboxylase coding gene. According to the invention, five key acyltransferase genes ata1-ata5 participating in acetylation of 5-HT in streptomyces albus are knocked out, so that the yield of 5-HT reaches 752.72 + / -94.28 mg / L under laboratory conditions, and an efficient biological manufacturing scheme is provided for industrial production of 5-HT.

The invention discloses a streptomyces strain and an application of the streptomyces strain in production of nystatin A1. The streptomyces disclosed by the invention is streptomyces albus J1074-nystatin BGC-SSC133, and the preservation number of the streptomyces albus is CGMCC (China General Microbiological Culture Collection Center) No.36300 in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms). Experiments prove that the streptomyces albus J1074-nystatin BGC-SSC133 can be used for efficiently preparing the nystatin A1, and the content of the nystatin A1 reaches 106.30 [mu] g / mL + / -8.45 [mu] g / mL. The method has important economic value and application prospect.

This invention discloses a novel antitumor macrolide compound, UCN370, its preparation method, and its applications. The structural formula of compound UCN370 is shown below. This invention successfully expressed the bacterial artificial chromosome (BAC) plasmid pUCN370, containing the UCN370 biosynthetic gene cluster, using the chassis strain *Streptomyces albus* J1074, resulting in the novel scaffold compound UCN370. The novel antitumor macrolide compound UCN370 described in this invention exhibits potent inhibitory activity against tumor cells such as HK-2 and can be used to prepare antitumor drugs.